LENZ Therapeutics (NASDAQ:LENZ) Now Covered by Analysts at TD Cowen

TD Cowen began coverage on shares of LENZ Therapeutics (NASDAQ:LENZ) in a research note published on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $60.00 price objective on the stock.

LENZ Therapeutics Trading Up 3.4 %

Shares of LENZ opened at $24.40 on Tuesday. LENZ Therapeutics has a one year low of $14.42 and a one year high of $38.93. The stock has a 50 day moving average price of $24.10 and a 200 day moving average price of $27.03.

Institutional Trading of LENZ Therapeutics

Large investors have recently made changes to their positions in the company. Harbor Capital Advisors Inc. purchased a new stake in shares of LENZ Therapeutics during the fourth quarter worth approximately $1,270,000. Parkman Healthcare Partners LLC purchased a new stake in shares of LENZ Therapeutics during the third quarter worth approximately $3,308,000. Barclays PLC increased its position in shares of LENZ Therapeutics by 273.1% during the third quarter. Barclays PLC now owns 16,463 shares of the company’s stock worth $391,000 after purchasing an additional 12,051 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of LENZ Therapeutics during the third quarter worth approximately $743,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of LENZ Therapeutics by 197.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 123,371 shares of the company’s stock worth $2,929,000 after purchasing an additional 81,901 shares in the last quarter. 54.32% of the stock is currently owned by hedge funds and other institutional investors.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.